Federico A. A.
- Country
- Spain
- Department
- Servicio de Aparato Digestivo
Research Overview
- Long-term Safety, Tolerability, and Efficacy of Balinatunfib in Adults with Crohn's Disease or Ulcerative Colitis: A Multicenter Extension Study
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
- Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III Study
Data & Insights
Has run more than one trial at 391 of 617 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating moderately to severely active inflammatory bowel conditions, with particular focus on therapeutic interventions for both ulcerative colitis and Crohn's disease.
- Advanced Therapeutic Approaches
- Clinical Response Assessment
- Disease Activity Monitoring
Demonstrates expertise in evaluating novel treatment approaches for inflammatory bowel conditions.
Gastrointestinal Immunology
Shows significant involvement in studying immune-mediated gastrointestinal disorders, including eosinophilic esophagitis and its inflammatory mechanisms.
- Immune Response Evaluation
- Inflammatory Marker Analysis
- Histologic Assessment
Focuses on understanding immune system responses in gastrointestinal conditions.
Treatment Innovation
Actively involved in evaluating targeted therapies and biological treatments for gastrointestinal disorders.
- Novel Therapeutic Assessment
- Long-term Treatment Efficacy
- Treatment Response Monitoring
Specializes in investigating emerging therapeutic options for chronic inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.